How to Screen and Prevent Metabolic Syndrome in Patients of PCOS Early: Implications From Metabolomics.
How to Screen and Prevent Metabolic Syndrome in Patients of PCOS Early: Implications From Metabolomics.
复制标题
如何早期筛查和预防 PCOS 患者的代谢综合征：代谢组学的启示
DOI：
10.3389/fendo.2021.659268
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Zhao X;Feng X;Zhao X;Jiang Y;Li X;Niu J;Meng X;Wu J;Xu G;Hou L;Wang Y
Background Polycystic ovary syndrome (PCOS) is a complex reproductive endocrine disorder. And metabolic syndrome (MS) is an important bridge for PCOS patients to develop other diseases, such as diabetes and coronary heart disease. Our aim was to study the potential metabolic characteristics of PCOS-MS and identify sensitive biomarkers so as to provide targets for clinical screening, diagnosis, and treatment. Methods In this study, 44 PCOS patients with MS, 34 PCOS patients without MS, and 32 healthy controls were studied. Plasma samples of subjects were tested by ultraperformance liquid chromatography (UPLC) system combined with LTQ-orbi-trap mass spectrometry. The changes of metabolic characteristics from PCOS to PCOS-MS were systematically analyzed. Correlations between differential metabolites and clinical characteristics of PCOS-MS were assessed. Differential metabolites with high correlation were further evaluated by the receiver operating characteristic (ROC) curve to identify their sensitivity as screening indicators. Results There were significant differences in general characteristics, reproductive hormone, and metabolic parameters in the PCOS-MS group when compared with the PCOS group and healthy controls. We found 40 differential metabolites which were involved in 23 pathways when compared with the PCOS group. The metabolic network further reflected the metabolic environment, including the interaction between metabolic pathways, modules, enzymes, reactions, and metabolites. In the correlation analysis, there were 11 differential metabolites whose correlation coefficient with clinical parameters was greater than 0.4, which were expected to be taken as biomarkers for clinical diagnosis. Besides, these 11 differential metabolites were assessed by ROC, and the areas under curve (AUCs) were all greater than 0.7, with a good sensitivity. Furthermore, combinational metabolic biomarkers, such as glutamic acid + leucine + phenylalanine and carnitine C 4: 0 + carnitine C18:1 + carnitine C5:0 were expected to be sensitive combinational biomarkers in clinical practice. Conclusion Our study provides a new insight to understand the pathogenesis mechanism, and the discriminating metabolites may help screen high-risk of MS in patients with PCOS and provide sensitive biomarkers for clinical diagnosis.
登录
查看更多内容
多囊卵巢综合征中新型脂质谱的发现：胰岛素和雄激素是否相反地调节生物活性脂质的产生？
DOI：
10.1210/jc.2016-2692
发表时间：
2017-03-01
期刊：
The Journal of clinical endocrinology and metabolism
影响因子：
--
作者：
Li S;Chu Q;Ma J;Sun Y;Tao T;Huang R;Liao Y;Yue J;Zheng J;Wang L;Xue X;Zhu M;Kang X;Yin H;Liu W
通讯作者：
Liu W
DOI：
10.1152/ajpendo.00471.2005
发表时间：
2006-07-01
影响因子：
5.1
作者：
Krogh-Madsen, Rikke;Plomgaard, Peter;Pedersen, Bente K.
通讯作者：
Pedersen, Bente K.
影响因子：
6.1
作者：
Lian Jiang-shan;Liu Wei;Huang Jian-rong
通讯作者：
Huang Jian-rong
影响因子：
1.6
作者：
Holvoet, P
通讯作者：
Holvoet, P
影响因子：
6.1
作者：
Fauser, BCJM;Chang, J;Lobo, R
通讯作者：
Lobo, R